We will use cookies and other information to optimize your experience. By continuing to browse, you consent to our use. For details, please read Privacy Policy
Gongwin Biopharm Co., Ltd.
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • Company presentation
    • History
    • Our Team
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • News&Media
    • Press Release
    • Latest Updates
    • Events
  • Pipeline
  • Products
    • Product Features
      • DM
    • PTS302 NSCLC-SMAO
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS100 HCC
      • Medical column
      • Treatment Result or Case
      • Clinical Trials
      • Pipeline development milestones
    • PTS-02 ACC
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS500 MPE
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • Anti-tumor drug for canine use
      • DM
      • Introduction
      • Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
      • History of Animal Clinical Trials
      • Case Acceptance Indications
      • Superficial malignant tumor in canine
      • Malignant melanoma of the canine
      • Lipoma of the canine and feline
      • Malignant bladder tumor of the canine and feline
      • Video
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Youtube
  • Contact
  1. Home
  2. Investors
DOMINOInterior Design
Investors
  • Financial information
    • Company annual report
    • Financial report
    • Monthly revenue
    • Legal person briefing
  • Corporate Governance
    • Corporate governance structure
    • Board of Directors
    • Committee
    • Internal audit
    • Company regulations
    • Other corporate governance information
  • Shareholder area
    • Shareholders' meeting
    • Dividend distribution
    • Material message
    • Stock price message
    • Investor Relations Contact Window
    • Stock agency
  • Interest relationship
    • Interested parties communicate with the company
Financial report
  1. Financial information
  2. Financial report
  • 012019.10
    Financial report
CONTACTS
  • Gongwin Biopharm Holdings Co., Ltd.
  • 02-2503-5282
  • E-mail info@gongwinbiopharm.com
  • Address 3F., No.80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 104, Taiwan (R.O.C.)
NAVIGATION
  • About Us
  • News&Media
  • Pipeline
  • Progress
  • Products
  • R & D
  • Investors
  • Join Us
  • Youtube
  • Video
  • Facebook
  • Contact
  • Terms
  • Disclaimer
Facebook fan page

Copyright © 2018 Gongwinbiopharm All rights reserved. Web Design | DMO

  • 繁體中文
  • English
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • Company presentation
    • History
    • Our Team
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • News&Media
    • Press Release
    • Latest Updates
    • Events
  • Pipeline
  • Products
    • Product Features
      • DM
    • PTS302 NSCLC-SMAO
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS100 HCC
      • Medical column
      • Treatment Result or Case
      • Clinical Trials
      • Pipeline development milestones
    • PTS-02 ACC
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS500 MPE
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • Anti-tumor drug for canine use
      • DM
      • Introduction
      • Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
      • History of Animal Clinical Trials
      • Case Acceptance Indications
      • Superficial malignant tumor in canine
      • Malignant melanoma of the canine
      • Lipoma of the canine and feline
      • Malignant bladder tumor of the canine and feline
      • Video
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Youtube
  • Contact